Search research articles
Contact Us
Filters
Showing results (191-200 of 212) with videos related to
Page
of 22
Sort By:
The Lancet. Haematology
|
June 12, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
Umberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Emanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
American Journal of Hematology
|
April 2, 2020
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study
Frédéric Baron, Fabio Efficace, Laura Cannella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2021
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Grzegorz S Nowakowski, Annalisa Chiappella, Randy D Gascoyne, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
The Lancet. Haematology
|
December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial
Marco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Cancers
|
January 11, 2022
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial
Gian Maria Zaccaria, Simone Ferrero, Eva Hoster, et al.
The Lancet. Haematology
|
June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
British Journal of Haematology
|
July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Francesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Hemasphere
|
March 24, 2025
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients
Rita Tavarozzi, Simone Ferrero, Andrea Evangelista, et al.
Page
of 22
Search research articles
Search
Showing results (191-200 of 212) with videos related to
Sort By:
Page
of 22
The Lancet. Haematology
|
June 12, 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial
Umberto Vitolo, Juan Miguel Bergua Burgues, Johannes Duell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2017
Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy
Emanuele Zucca, Annarita Conconi, Giovanni Martinelli, et al.
American Journal of Hematology
|
April 2, 2020
Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study
Frédéric Baron, Fabio Efficace, Laura Cannella, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 23, 2021
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Grzegorz S Nowakowski, Annalisa Chiappella, Randy D Gascoyne, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
The Lancet. Haematology
|
December 28, 2020
Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial
Marco Ladetto, Sergio Cortelazzo, Simone Ferrero, et al.
Cancers
|
January 11, 2022
A Clinical Prognostic Model Based on Machine Learning from the Fondazione Italiana Linfomi (FIL) MCL0208 Phase III Trial
Gian Maria Zaccaria, Simone Ferrero, Eva Hoster, et al.
The Lancet. Haematology
|
June 18, 2024
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
Kim M Linton, Umberto Vitolo, Wojciech Jurczak, et al.
British Journal of Haematology
|
July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Francesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Hemasphere
|
March 24, 2025
Long-term results of the FIL MCL0208 trial of lenalidomide maintenance versus observation after ASCT in MCL patients
Rita Tavarozzi, Simone Ferrero, Andrea Evangelista, et al.
Page
of 22